ノバルティス

 NVSのチャート


 NVSの企業情報

symbol NVS
会社名 Novartis AG Basel (ノバルティス)
分野(sector)   
産業(industry)   
業種 医薬品   医療関連(Health Care)
概要 ノバルティス(Novartis AG)はヘルスケア・ソリューションを提供する持株会社である。同社は医薬品を主としてヘルスケア製品の研究・開発・製造・販売に従事する。同社の事業は医薬品、サンドズ、アルコンとコーポレート活動を含む。医薬品事業は患者と医療提供者のための健康成果を開発するために特許を取得した処方薬を研究、開発、製造、販売、販売する。サンドズ事業は処方薬、有効・執行可能な第三者特許で保護されない医薬品有効成分を開発、製造、販売する。アルコン事業はアイケア製品を研究、開発、製造、販売する。アルコン事業は眼科医療機器と視力ケア製品の提供を行う。同社の製品には、医薬品、腫瘍薬、ジェネリック医薬品、バイオシミラー薬、眼科機器を有する。  ノバルティスはスイスの大手医薬品・バイオテクノロジ―企業。心血管代謝、免疫抑制、皮膚病、網膜、呼吸器など広範な領域で処方薬の研究、開発、生産、販売を展開。また、ジェネリック医薬品の開発、生産、販売に加え、眼科用医療機器、眼科手術器具・消耗品、コンタクトレンズや洗浄液などのアイケア製品も扱う。同社の製品は約180カ国で販売される。  
本社所在地 Lichtstrasse 35 Basel CH-4056 CHE
代表者氏名 Vasant Narasimhan
代表者役職名 Chief Executive Officer Member of the Executive Committee
電話番号 +41 61-324-1111
設立年月日 1895年7月
市場名 NYSE(ニューヨーク証券取引所)
ipoyear
従業員数 125161人
url www.novartis.com
nasdaq_url
adr_tso
EBITDA (百万ドル) 17697.00000
終値(lastsale)
時価総額(marketcap)
時価総額 (百万ドル) 240518.10000
売上高 (百万ドル) 53166.00000
企業価値(EV) (百万ドル) 256702.10000
当期純利益 (百万ドル) 12611.00000
決算概要 BRIEF: For the fiscal year ended 31 December 2018 Novartis AG (ADR) revenues increased 6% to $53.17B. Net income before extraordinary items increased 65% to $12.61B. Revenues reflect Innovative Medicines segment increase of 8% to $34.89B Alcon segment increase of 6% to $7.15B Other Foreign- segment increase of 6% to $22.17B United States segment increase of 4% to $17.56B Germany segment increase of 13% to $4.18B.

 NVSのテクニカル分析


 NVSのニュース

   Biosimilars Market to Show Incredible Growth and Forecast by 2031 | Pfizer Inc., Novartis AG, Amgen Inc., Biocon, Samsung Bioepis  2022/08/03 13:20:09 Express Press Release Distribution
New York, 2022-Aug-03 — /EPR Network/ — According to a new market research report published by Global Insight Services “Biosimilars Market” is expected to reach [read full press release…]
   GSK plc – Consensus Indicates Potential 47.6% Upside  2022/08/03 10:47:13 DirectorsTalk
GSK plc found using ticker (GSK) have now 3 analysts in total covering the stock. The consensus rating is ''Buy''. The range between the high target price and low target price is between 63.75 and 57.42 with a mean TP of 61.43. Now with the previous closing price of 41.63 this is indicating there is a potential upside of 47.6%. There is a 50 day moving average of 42.89 while the 200 day moving average is 43.85. The market capitalisation for the company is $84,612m. Visit the company website at: https://www.gsk.com [stock_market_widget type="chart" template="basic" color="green" assets="GSK" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $124,855m based on the market concensus. GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally.
   Cell Line Development Market Expected to Grow at a CAGR of 13.4% from 2022-2030 | Exclusive MDC Research Study  2022/08/01 00:02:00 Benzinga
Pune, July 31, 2022 (GLOBE NEWSWIRE) -- Cell Line Development Market by Vendor Assessment, Technology Assessment, Partner & Customer Ecosystem, type/solution, service, organization size, end-use verticals, and Region – Global Cell Line Development Market Forecast to 2030, published by Market Data Centre, The Cell Line Development Market is projected to grow at a solid pace during the forecast period. The presence of key players in the ecosystem has led to a compsetitive and diverse market. The advancement of digital transformation initiatives across multiple industries is expected to drive the worldwide Cell Line Development Market during the study period. This COVID-19 analysis of the report includes COVID-19 IMPACT on the production and, demand, supply chain. This report provides a detailed historical analysis of the global Cell Line Development Market from 2017-to 2021 and provides extensive market forecasts from 2022-to 2030 by region/country and subsectors. The report covers the revenue, sales volume, price, historical growth, and future perspectives in the Cell Line Development Market.
   Vanguard Global ESG Select Stock Profits from ESG Leaders  2022/07/29 15:48:27 Kiplinger
It was a bit late to the party, but Vanguard Global ESG Select Stock ( VEIGX ) is having a blast so far. The fund launched in 2019—well into the ESG investing trend, which places as much value on environmental, social and corporate governance criteria as on financial measures when selecting stocks. Over the past three years, managers Mark Mandel and Yolanda Courtines, of subadvisory firm Wellington Management, have delivered a 10.1% annualized return. That beat the fund’s bogey, the FTSE All-World index, as well as the typical global large-company stock fund with an ESG focus. Mandel and Courtines pick profitable, well-run firms around the globe that are leaders in integrating ESG practices into their businesses. They focus on companies that have a market value of more than $20 billion and score well on stewardship, says Mandel. That means the firm’s board members are steering the company toward a future that rewards all stakeholders, including employees, shareholders and the planet. SEE MORE Kiplinger ESG 20: Our Favorite Picks for ESG Investors Take farm equipment giant Deere ( DE ), one of the fund’s 37 holdings.
   Novartis AG – Consensus Indicates Potential 17.6% Upside  2022/07/29 09:48:41 DirectorsTalk
Novartis AG with ticker code (NVS) now have 4 analysts covering the stock. The analyst consensus points to a rating of ''Buy''. The range between the high target price and low target price is between 105 and 97 and has a mean target at 102. Given that the stocks previous close was at 86.75 this now indicates there is a potential upside of 17.6%. The 50 day moving average now sits at 85.87 and the 200 moving average now moves to 85.79. The market capitalisation for the company is $190,470m. Find out more information at: https://www.novartis.com [stock_market_widget type="chart" template="basic" color="green" assets="NVS" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $223,953m based on the market concensus. Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers.
   NVS Recruitment 2022 - PGT, TGT Vacancy, Latest Jobs  2022/07/07 06:07:20 The Sentinel Assam
Navodaya Vidyalaya Samiti (NVS) released latest job notification for the recruitment of PGT, TGT Jobs in NVS. Interested candidates can apply before the last date. Check more details on NVS job vacancy 2022. NVS Job Notification 2022 Navodaya Vidyalaya Samiti published a job notification to fill up PGT, TGT vacancies. NVS Post Details, Qualifications, Salary Scale Given below:- Navodaya Vidyalaya Samiti Job Openings About NVS Job Requirement Details Post Name PGT, TGT No. of Post 584 Salary Rs.44900-209200/- Per Month Job Location Arunachal Pradesh – Assam – Manipur – Meghalaya – Mizoram – Nagaland – Sikkim – Tripura Age Limit the candidate''s maximum age should be 50 years as on 01-07-2022 Application Fee Principal Post: All Candidates: Rs.2000 PGT Post: All Candidates: Rs.1800/- TGT, Music/Art Teacher, PET, Librarian Posts: All Candidates: Rs.1500/- SC/ST/PH Candidates: Nil Mode of Payment: Online Selection Process Computer Based Test and Interview/ Personal Interaction Last Date 29-Jul-2022 Last Date to pay the application fee 29-07-2022 Website navodaya.
   Novartis debuted its first integrated sustainability and finance report this year — more companies are likely to follow suit  2022/07/06 19:09:03 Business Insider
The global pharmaceutical company, Novartis, released its first-ever integrated social impact report. The report connects sustainability goals and business objectives.
   Multiple Sclerosis Therapeutics Market Huge Growth in Future Scope 2022-2028 | Novartis AG, Teva Pharmaceutical Industries Ltd., Sanofi S.A., Bayer AG, Pfizer, Inc.  2022/07/06 14:18:34 OpenPR
The exclusive research report on ''Multiple Sclerosis Therapeutics Market'' now available with , offers a detailed analysis of the factors influencing the global business sphere. This report also provides precise information pertaining to market size, commercialization aspects and
   Novartis Stock: A Safe Bear Market Value Buy Now Yielding 4% (NYSE:NVS)  2022/07/06 12:15:11 Seeking Alpha
Novartis maintains strong profitability & NVS is now trading in value territory. Is this an opportunity to layer into this quality stock? Click here to find out.
   Novartis Is Awakening From Lethargy (NYSE:NVS)  2022/07/06 10:04:55 Seeking Alpha
Novartis'' (NVS) product portfolio was a reason for skepticism for some time. Read more to see why I believe that Novartis is getting back on track.
   Celldex Therapeutics Skids As It Takes On A Blockbuster Roche, Novartis Drug  2022/07/01 14:11:03 Investor''s Business Daily
Celldex took aim at Roche and Novartis'' blockbuster hives drug on Friday with a small study that showed promise — but CLDX stock tumbled.
   Everything You Need to Know If You’re Worried About Recession  2022/07/01 07:34:31 TipRanks
This week, the Chairman of the Federal Reserve, Jerome Powell, spoke at an economic forum hosted by the European Central Bank and talked about inflation and efforts to combat it. In this video, let''s find what the Fed Chief said and what we can expect in the near future. Further in the video, we will talk about job cuts at JPMorgan (JPM), Novartis (NVS) and crypto firm Crypto.com. Finally, we will look at California’s inflation relief checks and the latest key economic data that could influence Fed’s next move in its battle against inflation.
   Novartis buys Mallinckrodt''s FDA voucher for $100M but remains mum on where to use its 7th PRV  2022/06/30 18:17:26 Endpoints News
Novartis on Thursday confirmed to Endpoints News that it purchased a priority review voucher from bankrupt pharma company Mallinckrodt, but the Swiss-American multinational company declined to elaborate on how it plans to use this 7th PRV. Under the terms of the deal, PRV market leader Novartis agreed to pay $65
   Novartis opens new plant in Mumbai  2022/06/30 17:16:09 Economic Times India
Novartis on Friday said it has opened its new manufacturing plant for generic oral cancer medicines at Kalwe in Mumbai. Spread across 32,000 sqm, and housing state-of-the-art production technology, the plant is built to cater to export markets. It currently has a workforce of 70 people with plans to increase further to support the expansion of production capacity and capabilities.Built on a brownfield site, the plant has effluent treatment units installed to support sustainable manufacturing operations.Novartis said the plant, which marks a new chapter for its Sandoz business, will further strengthen the company’s operations in India and play a key role in driving global growth for its generics business.“Today marks an important milestone for us at Novartis, and particularly for our Sandoz division, a global leader in generic pharmaceuticals and biosimilars. The inauguration of the new production and launch site for Oncology oral solids at Kalwe in India is a step forward in our constant endeavour to pioneeraccess for patients by developing and commercializing novel, affordable approaches that address unmet medical needs," said Sanjay Murdeshwar, country president, Novartis India.
   Novartis weighs listing of $25B generic unit – Bloomberg  2022/06/30 16:57:44 Seeking Alpha
Swiss drugmaker, Novartis AG (NVS) (NVSEF) is said to be leaning towards a potential spinoff of its Sandoz business and a separate listing of the $25B generics drug unit is…

 関連キーワード  (医薬品 米国株 ノバルティス NVS )

 twitter  (公式ツイッターやCEOツイッターなど)

NVS動画